韩国WHO二级胶质瘤患者治疗模式的多中心研究:KNOG 15-02与KROG 16-04联合研究
该多中心研究纳入2000至2010年间韩国14家机构诊断的555例WHO二级胶质瘤患者,按辅助治疗分为单纯放疗组(204例)、单纯化疗组(20例)、放化疗联合组(65例)和无辅助治疗组(266例)。结果显示放疗是最常用的辅助治疗,2008年后化疗(联合或不联合放疗)使用率从38%降至4%,PCV为主要化疗方案但替莫唑胺比例自2005年升至69%。与放疗相关的因素包括男性、无癫痫发作、多脑叶受累和非全切除;化疗与全切除和星形细胞瘤相关。
要点
- 放疗是韩国WHO二级胶质瘤最常用的辅助治疗方式。
- 2008年后化疗(联合或不联合放疗)使用率从38%降至4%。
- 切除程度与决定是否进行放疗和化疗相关。
核心结论
- 韩国WHO二级胶质瘤的治疗模式显示放疗偏好和替莫唑胺使用增加,切除程度与辅助治疗决策相关。
- 为建立可靠的LGG指南,需要纳入分子信息的进一步研究。
研究设计与样本
- 多中心研究纳入2000至2010年间韩国14家机构诊断的555例WHO二级胶质瘤患者。
- 患者按辅助治疗分为四组:单纯放疗组(N=204)、单纯化疗组(N=20)、放化疗联合组(N=65)和无辅助治疗组(N=266)。
主要发现
- 星形细胞瘤210例(38%),少突星形细胞瘤85例(15%),少突胶质细胞瘤260例(47%)。
- 全切除200例(36%),次全切除153例(28%),部分切除71例(13%),活检131例(24%)。
- 放疗是最常用的辅助治疗;化疗(联合或不联合放疗)使用率2008年后从38%降至4%。
- 主要化疗方案为丙卡巴肼、洛莫司汀和长春新碱(PCV),但替莫唑胺比例自2005年升至69%。
- 与放疗相关的患者/肿瘤特征为男性、无癫痫发作、多脑叶受累和非全切除;化疗与全切除和星形细胞瘤相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We performed this study to identify the treatment patterns of patients with low-grade gliomas (LGG) in Korea. METHODS: A total of 555 patients diagnosed as WHO grade II gliomas between 2000 and 2010 at 14 Korean institutions were included. The patients were divided into four adjuvant treatment groups: adjuvant fractionated radiotherapy (RT, N = 204), adjuvant chemotherapy (N = 20), adjuvant fractionated RT and chemotherapy (N = 65), and non-adjuvant treatment (N = 266) groups. We examined differences among the groups and validated patient/tumor characteristics associated with the adjuvant treatments. RESULTS: Astrocytoma was diagnosed in 210 patients (38%), oligoastrocytoma in 85 patients (15%), and oligodendroglioma in 260 patients (47%). Gross total resection was performed in 200 patients (36%), subtotal resection in 153 (28%), partial resection in 71 patients (13%), and biopsy in 131 patients (24%). RT was most commonly applied as an adjuvant treatment. The use of chemotherapy with or without RT decreased after 2008 (from 38 to 4%). The major chemotherapeutic regimen was procarbazine, lomustine, and vincristine (PCV); however, the proportion of temozolomide increased since 2005 (up to 69%). Patient/tumor characteristics related with RT were male gender, non-seizure, multiple lobes involvement, and non-gross total resection. Chemotherapy was associated with non-gross total resection and non-astrocytoma. CONCLUSIONS: A preference for RT and increased use of temozolomide was evident in the treatment pattern of LGG. The extent of resection was associated with a decision to perform RT and chemotherapy. To establish a robust guideline for LGG, further studies including molecular information are needed.
引用
- Koo T, Lim DH, Seol HJ, et al. Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. J Neurooncol. 2018. PMID: 29572674. doi:10.1007/s11060-018-2839-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。